Patents by Inventor Genevieve Almouzni
Genevieve Almouzni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230201264Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: March 2, 2023Publication date: June 29, 2023Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Christel GOUDOT, Luigia PACE, Genevieve ALMOUZNI
-
Patent number: 11622978Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: GrantFiled: January 20, 2020Date of Patent: April 11, 2023Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni, Leticia Niborski
-
Patent number: 11285176Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: GrantFiled: October 21, 2021Date of Patent: March 29, 2022Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRSInventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni, Leticia Niborski
-
Publication number: 20220040235Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: October 21, 2021Publication date: February 10, 2022Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Christel GOUDOT, Luigia PACE, Genevieve ALMOUZNI
-
Publication number: 20200171090Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: January 20, 2020Publication date: June 4, 2020Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Christel GOUDOT, Luigia PACE, Genevieve ALMOUZNI
-
Patent number: 10576103Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: GrantFiled: May 29, 2019Date of Patent: March 3, 2020Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALS (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRSInventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni
-
Publication number: 20190365807Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: May 29, 2019Publication date: December 5, 2019Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Christel GOUDOT, Luigia PACE, Genevieve ALMOUZNI
-
Publication number: 20190117664Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of T-helper type 2 (Th2)-mediated diseases. More particularly, the present invention relates to an inhibitor of the Suv39h1-HP1a silencing pathway for use in the treatment of a T-helper type 2 (Th2)-mediated disease, in particular allergic asthma.Type: ApplicationFiled: December 7, 2018Publication date: April 25, 2019Inventors: Sebastian AMIGORENA, Rhys ALLAN, Heidi SCHREIBER, Elina ZUEVA, Genevieve ALMOUZNI
-
Publication number: 20150038496Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of T-helper type 2 (Th2)-mediated diseases. More particularly, the present invention relates to an inhibitor of the Suv39h1-HP1a silencing pathway for use in the treatment of a T-helper type 2 (Th2)-mediated disease, in particular allergic asthma.Type: ApplicationFiled: October 3, 2012Publication date: February 5, 2015Inventors: Sebastian Amigorena, Rhys Allan, Heidi Schreiber, Elina Zueva, Genevieve Almouzni
-
Publication number: 20130149320Abstract: The present invention provides a prognostic marker in human cancer, Asf1b, a high expression thereof being associated with a poor prognosis. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy. Finally, the present invention provides a new therapeutic target for treating cancer.Type: ApplicationFiled: May 31, 2011Publication date: June 13, 2013Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIEInventors: Genevieve Almouzni, Armelle Corpet
-
Publication number: 20120046190Abstract: The present invention provides a prognostic marker in human cancer, HP1?, a high expression thereof being associated with a poor prognosis. The present invention further provides a method for diagnosing a cancer in a subject, HP1? a being specifically overexpressed in tumoral cells. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy and a method for monitoring the response of a subject affected with a cancer to a treatment.Type: ApplicationFiled: April 23, 2010Publication date: February 23, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIEInventors: Geneviève Almouzni, Leanne De Koning
-
Publication number: 20110003706Abstract: A method for assessing the proliferative state of cells in a human or non-human biological sample uses Chromatin Assembly Factor-1 (CAF-1) subunits as proliferation markers. The method can be used for breast cancer prognosis or diagnosis, and monitoring tumor response in therapy.Type: ApplicationFiled: June 3, 2010Publication date: January 6, 2011Applicants: Institut Curie, Centre National de la Recherche Scientifique(CNRS), Université Pierre et Marie Curie (Paris VI)Inventors: Genevieve ALMOUZNI, Sophie E. POLO, Stamatios E. THEOCHARIS, Philippe VIELH
-
Patent number: 7781174Abstract: The invention relates to a method for assessing the proliferative state of cells in a human or non human biological sample, comprising using Chromatin Assembly Factor-1 (CAF-1 in short) subunits as proliferation markers. Application for cancer prognosis or diagnosis and monitoring tumor response in therapy.Type: GrantFiled: August 28, 2006Date of Patent: August 24, 2010Assignees: Institut Curie, Centre National de la Recherche Scientifique (CNRS), Universite Pierre et Marie CurieInventors: Genevieve Almouzni, Sophie E. Polo, Stamatios E. Theocharis, Philippe Vielh
-
Publication number: 20070077577Abstract: The invention relates to a method for assessing the proliferative state of cells in a human or non human biological sample, comprising using Chromatin Assembly Factor-1 (CAF-1 in short) subunits as proliferation markers. Application for cancer prognosis or diagnosis and monitoring tumor response in therapy.Type: ApplicationFiled: August 28, 2006Publication date: April 5, 2007Applicants: Institut Curie, Centre National de la Recherche Scientifique (CNRS), Universite Pierre et Marie Curie (Paris VI)Inventors: Genevieve Almouzni, Sophie Polo, Stamatios Theocharis, Philippe Vielh